Impel Neuropharma Inc (IMPL) Peer Comparison
$0.02
$0.00
(-21.50%)
As on 16-Feb-2024 09:30EDT
Market cap
$6 Mln
Revenue (TTM)
$21 Mln
P/E Ratio
--
P/B Ratio
18.5
Div. Yield
0 %
Edit
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
6 | 8,724 | -- | 3 | 1 |
Revenue ($ Mln) |
21 | 288 | 482 | 7 | -- |
Net Profit ($ Mln) |
-96.11 | -73.07 | -1,440.62 | -81.15 | -22.03 |
Net Margin (%) |
-457.97 | -24.98 | -287.92 | 323.98 | -- |
RoE (%) |
-- | -21.38 | -- | -- | -- |
Price to Earnings |
-- | -- | -- | -- | -- |
Price-To-Book |
18.46 | 15.53 | -- | 1.73 | 0.44 |
Income Statement ($ Mln)
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
20.99 | 287.61 | 481.58 | 7.00 | 0.00 |
|
Cost of Revenue
|
9.95 | 3.87 | 350.95 | 53.39 | 0.00 |
|
Gross Profit
|
6.16 | 108.61 | 99.05 | 9.14 | -- |
|
Operating Expenses
|
81.14 | 363.93 | 633.77 | 66.27 | 30.21 |
|
Operating Profit (EBIT)
|
-70.11 | -80.19 | -1,461.42 | -26.07 | -30.21 |
|
Other Income
|
0.00 | 4.97 | 18.77 | -32.04 | 0.00 |
|
Profit before Tax
|
-74.28 | -72.59 | -1,454.03 | -39.85 | -24.14 |
|
Provision for Tax
|
24.27 | 0.48 | -13.41 | -18.08 | -2.65 |
|
Profit after Tax (Net Income)
|
-96.11 | -73.07 | -1,440.62 | -81.15 | -22.03 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Consolidated Profit
|
-23.04 | -73.52 | -1,440.62 | -79.08 | -22.70 |
Liabilities ($ Mln)
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-91.91 | 561.60 | -1,083.40 | 1.70 | -5.76 |
|
Minority Interest
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Non-Current Liabilities
|
2.24 | 125.85 | 1,460.10 | 1.57 | 2.56 |
|
Current Liabilities
|
124.74 | 134.66 | 158.42 | 9.78 | 12.32 |
|
Total Liabilities
|
88.55 | 348.94 | 1,954.12 | 62.15 | 20.68 |
Assets ($ Mln)
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
11.65 | 85.87 | 156.72 | 3.49 | 2.61 |
|
Current Assets
|
23.43 | 736.23 | 378.40 | 9.56 | 6.52 |
|
Total Assets
|
88.55 | 348.94 | 1,954.12 | 62.15 | 20.68 |
|
Total Debt*
|
114.80 | 72.11 | 1,508.38 | 2.43 | 2.55 |
|
Net Current Assets
|
-101.32 | 601.57 | 219.98 | -0.22 | -5.80 |
Cashflow ($ Mln)
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-93.64 | -229.80 | -492.96 | -65.08 | -45.97 |
|
Cash Flow from Investing Activities
|
-1.38 | -1.36 | -174.80 | -0.01 | -- |
|
Cash from Financing Activities
|
67.46 | 27.55 | 1.76 | 59.37 | 6.14 |
|
Net Cash Inflow / Outflow
|
-- | -203.61 | -- | -5.72 | -- |
Ratios
Profitability Ratios
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-290.92 | -130.31 | -94.77 | -247.00 | -305.47 |
|
ROE (%)
|
-3,099.99 | -21.38 | -201.69 | -306.06 | -350.17 |
|
ROA (%)
|
-67.46 | -10.30 | -101.70 | -182.82 | -64.53 |
|
EBIT Margin (%)
|
-338.27 | -27.37 | -91.51 | -1,216.78 | -- |
|
Net Margin (%)
|
-457.97 | -24.98 | -287.92 | 323.98 | -- |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | -- |
Growth Ratios
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
155.29 | 200.83 | -7.38 | -19.11 | -- |
|
EBIT Growth (%)
|
20.95 | 60.01 | 45.22 | -31.23 | 61.40 |
|
Net Profit Growth (%)
|
23.92 | 64.12 | 55.14 | -48.23 | 59.82 |
|
EPS Growth (%)
|
25.29 | 64.08 | 61.12 | 42.12 | 78.20 |
|
Book Value Growth (%)
|
-311.65 | 178.11 | -688.85 | -95.46 | 91.48 |
Valuation Ratios
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-0.69 | -5.66 | -0.15 | -1.03 | 0.00 |
|
Price / Book Value
|
-2.02 | 8.10 | 4.46 | 7.80 | 0.00 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-0.97 | -4.61 | -2.94 | -0.51 | 0.20 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.13 | -1.22 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
-1.22 | 0.04 | -0.04 | 1.25 | -0.12 |
|
Current Ratio
|
0.19 | 5.47 | 2.39 | 0.98 | 0.53 |
|
Quick Ratio
|
0.13 | 5.43 | 2.25 | 0.98 | 0.53 |
|
Interest Coverage
|
-1.79 | -17.35 | -37.30 | -0.19 | -0.88 |
Operating Efficiency Ratios
| Impel Neuropharma Inc (IMPL) | ImmunoGen (IMGN) | Invitae Corp (NVTA) | Aravive (ARAV) | ContraFect Corp (CFRX) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
31.41 | 45.44 | 17.13 | 0.00 | -- |
|
Asset Turnover
|
0.15 | 0.41 | 0.34 | 0.16 | 0.00 |
|
Receivable days
|
126.97 | 60.36 | 57.43 | 2.36 | -- |
|
Inventory Days
|
316.35 | -13,268.33 | 27.97 | -7.76 | -- |
|
Payable days
|
350.32 | 94,120.36 | 15.37 | 31.16 | -- |
|
Cash Conversion Cycle
|
93.00 | -107,328.32 | 70.04 | -36.56 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
